

State or territory	Locality	Season start	Season end	Lodging	M&IE	Total per diem	Effective date
PUERTO RICO .....	FAJARDO [INCL ROOSEVELT RDS NAVSTAT].	01/01	12/31	139	92	231	10/01/2012
PUERTO RICO .....	FT. BUCHANAN [INCL GSA SVC CTR, GUAYNABO].	12/01	05/31	195	88	283	12/01/2015
PUERTO RICO .....	FT. BUCHANAN [INCL GSA SVC CTR, GUAYNABO].	06/01	11/30	167	88	255	12/01/2015
PUERTO RICO .....	HUMACAO .....	01/01	12/31	139	92	231	10/01/2012
PUERTO RICO .....	LUIS MUNOZ MARIN IAP AGS .....	12/01	05/31	195	88	283	12/01/2015
PUERTO RICO .....	LUIS MUNOZ MARIN IAP AGS .....	06/01	11/30	167	88	255	12/01/2015
PUERTO RICO .....	LUQUILLO .....	01/01	12/31	139	92	231	10/01/2012
PUERTO RICO .....	MAYAGUEZ .....	01/01	12/31	109	112	221	09/01/2010
PUERTO RICO .....	PONCE .....	01/01	12/31	149	89	238	09/01/2012
PUERTO RICO .....	RIO GRANDE .....	01/01	12/31	169	123	292	06/01/2012
PUERTO RICO .....	SABANA SECA [INCL ALL MILITARY].	12/01	05/31	195	88	283	12/01/2015
PUERTO RICO .....	SABANA SECA [INCL ALL MILITARY].	06/01	11/30	167	88	255	12/01/2015
PUERTO RICO .....	SAN JUAN & NAV RES STA .....	06/01	11/30	167	88	255	12/01/2015
PUERTO RICO .....	SAN JUAN & NAV RES STA .....	12/01	05/31	195	88	283	12/01/2015
PUERTO RICO .....	VIEQUES .....	01/01	12/31	175	95	270	03/01/2012
VIRGIN ISLANDS (U.S.) .....	ST. CROIX .....	12/15	04/14	299	116	415	06/01/2015
VIRGIN ISLANDS (U.S.) .....	ST. CROIX .....	04/15	12/14	247	110	357	06/01/2015
VIRGIN ISLANDS (U.S.) .....	ST. JOHN .....	12/04	04/30	230	113	343	08/01/2015
VIRGIN ISLANDS (U.S.) .....	ST. JOHN .....	05/01	12/03	170	107	277	08/01/2015
VIRGIN ISLANDS (U.S.) .....	ST. THOMAS .....	04/15	12/15	249	110	359	03/01/2017
VIRGIN ISLANDS (U.S.) .....	ST. THOMAS .....	12/16	04/14	339	110	449	03/01/2017
WAKE ISLAND .....	WAKE ISLAND .....	01/01	12/31	129	70	199	09/01/2019

\* Where meals are included in the lodging rate, a traveler is only allowed a meal rate on the first and last day of travel.

[FR Doc. 2019-18690 Filed 8-28-19; 8:45 am]

BILLING CODE 5001-06-P

## DEPARTMENT OF DEFENSE

### Office of the Secretary

#### Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting

**AGENCY:** Under Secretary of Defense for Personnel and Readiness, Department of Defense (DoD).

**ACTION:** Notice of Federal Advisory Committee meeting.

**SUMMARY:** The Department of Defense (DoD) is publishing this notice to announce that the following Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel will take place.

**DATES:** Open to the public Wednesday, September 25, 2019, from 9:00 a.m. to 12:00 p.m.

**ADDRESSES:** The address of the open meeting is the Naval Heritage Center Theater, 701 Pennsylvania Avenue NW, Washington, DC 20004. FOR

**FOR FURTHER INFORMATION CONTACT:** Colonel Paul J. Hoerner, USAF, 703-681-2890 (Voice), [dha.ncr.j-6.mbx.baprequests@mail.mil](mailto:dha.ncr.j-6.mbx.baprequests@mail.mil) (Email). Mailing address is 7700 Arlington Boulevard, Suite 5101, Falls Church, VA 22042-5101. Website: [https://](https://health.mil/bap)

[health.mil/bap](https://health.mil/bap). The most up-to-date changes to the meeting agenda can be found on the website.

**SUPPLEMENTARY INFORMATION:** This meeting is being held under the provisions of the Federal Advisory Committee Act (FACA) of 1972 (5 U.S.C., Appendix, as amended), the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended), and 41 Code of Federal Regulations (CFR) 102-3.140 and 102-3.150. The Panel will review and comment on recommendations made to the Director of the Defense Health Agency, by the Pharmacy and Therapeutics Committee, regarding the Uniform Formulary.

**Purpose of the Meeting:** The DoD is publishing this notice to announce that the following Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel will take place.

#### Agenda

1. Sign-In
2. Welcome and Opening Remarks
3. Scheduled Therapeutic Class Reviews (Comments will follow each agenda item)
  - a. Multiple Sclerosis Agents—Interferon
  - b. Multiple Sclerosis Agents—Methyl Fumarate
  - c. Corticosteroids—Immune Modulators—High Potency
4. Newly Approved Drugs Review

#### 5. Pertinent Utilization Management Issues

#### 6. Panel Discussions and Vote

**Meeting Accessibility:** Pursuant to 5 U.S.C. 552b, as amended, and 41 CFR 102-3.140 through 102-3.165, and the availability of space, this meeting is open to the public. Seating is limited and will be provided only to the first 220 people signing-in. All persons must sign-in legibly.

**Written Statements:** Pursuant to 41 CFR 102-3.140, the public or interested organizations may submit written statements to the membership of the Panel about its mission and/or the agenda to be addressed in this public meeting. Written statements should be submitted to the Panel's Designated Federal Officer (DFO). The DFO's contact information can be obtained previously in this notice. Written comments or statements must be received by the committee DFO at least five (5) business days prior to the meeting so that they may be made available to the Panel for its consideration prior to the meeting. The DFO will review all submitted written statements and provide copies to all the committee members.

Dated: August 23, 2019.

**Aaron T. Siegel,**

*Alternate OSD Federal Register Liaison Officer, Department of Defense.*

[FR Doc. 2019-18593 Filed 8-28-19; 8:45 am]

BILLING CODE 5001-06-P